Sarcopenia in Menopause: How to Reverse Accelerated Muscle Loss

Sarcopenia in menopause is largely reversible through progressive resistance training combined with adequate protein intake (1.4-1.6g per kg body weight per day). Maltais and colleagues at the Université de Sherbrooke documented in their 2009 review that postmenopausal women lose muscle at roughly twice the rate of premenopausal women of equivalent age, with declines of 3-8% per decade across midlife unless resistance training is in place [1]. The 2022 Capel-Alcaraz systematic review on resistance training in postmenopausal women found consistent muscle preservation and modest gain across pooled trials [2]. The Liu and Latham 2009 Cochrane review of progressive resistance training in older adults pooled 121 trials and over 6,000 participants, concluding the intervention is effective and safe when properly programmed [3]. Sarcopenia is a real and accelerating problem after menopause, and it is also one of the most reversible.

At a glance: what reverses menopausal sarcopenia

Intervention	Evidence strength	How long it takes	Practical take
Progressive resistance training, 2-3x/week	Strongest (Capel-Alcaraz 2022 [2], Liu & Latham 2009 Cochrane [3])	8-16 weeks for measurable muscle change	The non-negotiable foundation. Compound lifts, progressive overload.
Adequate protein (1.4-1.6g/kg/day)	Strong (Phillips 2016 [4])	Effects compound with training	Most postmenopausal women under-eat protein significantly.
Compound movements with progressive overload	Strong	Same as above	Squat, hinge, push, pull, carry. Add weight every 2-4 weeks.
Adequate sleep (7-9 hours)	Strong indirect	Effects compound with training	Muscle protein synthesis is sleep-dependent.
Walking and aerobic exercise	Modest direct, strong supporting	Cumulative	Supports recovery and metabolic health, doesn’t build muscle.
Protein distribution across 3-4 meals	Moderate (Aragon & Schoenfeld [5])	Effects accrue with consistency	25-35g protein per meal beats 100g in one dose.
HRT in early postmenopause	Modest supportive evidence	Variable	May enhance muscle protein synthesis response in some women.
Bodyweight-only training long-term	Inadequate for muscle gain	Plateaus quickly	Useful as on-ramp, not as long-term sarcopenia prevention.

What sarcopenia is and why menopause accelerates it

Sarcopenia is the age-related loss of muscle mass and strength, defined clinically by the European Working Group on Sarcopenia in Older People (EWGSOP2) as the presence of both low muscle strength and low muscle quantity or quality. The condition was first named by Rosenberg in 1989 and has since become recognised as a major contributor to functional decline, falls, fractures and reduced independence in older adults. The Cruz-Jentoft 2019 EWGSOP2 consensus paper provided the current diagnostic framework [6]. The menopausal transition accelerates muscle loss substantially, which is why women in their 50s and 60s often notice strength and functional changes that didn’t appear in their 40s.

The biology runs through several pathways at once. Oestrogen has direct roles in muscle protein synthesis and satellite cell activation; its decline reduces the muscle-building response to both food intake and exercise. Anabolic resistance (the reduced ability of older muscle to respond to dietary protein) accelerates after menopause. The growth hormone and IGF-1 signalling that supports muscle maintenance also declines. The combined effect is a hormonal environment less favourable to muscle preservation than the premenopausal one.

The numbers matter. Maltais and colleagues documented that postmenopausal women lose muscle at roughly twice the premenopausal rate, with declines of 3-8% per decade across midlife in untrained populations [1]. By 70, untrained women have typically lost 25-35% of the peak muscle mass they had at 30. The functional consequences (slower gait, weaker grip, less stair-climbing capacity, higher fall risk) compound over decades.

The metabolic consequences matter as much as the functional ones. Lean muscle tissue burns roughly 13 calories per kg per day at rest. Loss of 5kg of muscle reduces resting metabolic rate by roughly 65 calories per day. Combined with the gradual fat gain that often accompanies sarcopenia, the body composition shift over a decade can be substantial even when scale weight changes modestly.

Why does this matter for an exercise guide? Because the standard message that “you naturally lose muscle as you age, there’s nothing to be done” is wrong. Sarcopenia is largely reversible through appropriate training and nutrition. Women who train consistently through their 50s, 60s and 70s maintain or build muscle in patterns that look very different from the average untrained trajectory. The intervention works; the question is whether it gets implemented.

Why exercise specifically reverses sarcopenia

Resistance training reverses sarcopenia through three pathways: direct mechanical stimulus to muscle protein synthesis, hormonal effects (acute growth hormone and IGF-1 release), and improved sensitivity of muscle to dietary protein over weeks to months. Westcott’s 2012 review in Current Sports Medicine Reports mapped the broad health effects of resistance training and identified muscle preservation as one of the most consistently documented benefits in postmenopausal populations [7]. The 2022 Capel-Alcaraz systematic review confirmed and updated this evidence [2].

The mechanical stimulus pathway is the most direct. Heavy or near-failure resistance training creates micro-damage to muscle fibres that triggers protein synthesis to repair and build. The mTOR (mammalian target of rapamycin) signalling pathway is the central molecular switch. Repeated stimulation across weeks produces measurable hypertrophy. The dose-response is well-characterised in mixed adult populations and translates reasonably to postmenopausal women.

The hormonal pathway operates through both acute and chronic effects. Acute resistance training elevates growth hormone and IGF-1 in the post-exercise window, supporting protein synthesis. Chronic training improves the receptor sensitivity for these signals. Even though the absolute hormone levels in postmenopausal women are lower than in premenopausal women, the response to training remains intact.

The protein sensitivity pathway is the most recently characterised and matters most for the menopause-specific picture. Anabolic resistance (the reduced ability of older muscle to respond to dietary protein) is partially reversible through resistance training. Trained postmenopausal women show better muscle protein synthesis response to a protein meal than untrained postmenopausal women, which means the same dietary protein produces more muscle-building effect when training is in place.

The combined effect of these pathways is that resistance training plus adequate protein produces muscle gain even in postmenopausal women, despite the unfavourable hormonal background. The Liu and Latham 2009 Cochrane review on progressive resistance training in older adults included plenty of women in their 60s and 70s and documented consistent strength and function improvements [3]. Sarcopenia is not destiny.

Resistance training: the primary intervention

Progressive resistance training is the single highest-evidence intervention for reversing menopausal sarcopenia, with the Capel-Alcaraz 2022 systematic review documenting consistent muscle preservation and modest gain across pooled trials in postmenopausal women. The protocol that produces these effects is well-established: 2-3 sessions per week, full-body or upper/lower split, compound movements with progressive overload, 6-15 reps per set with weights challenging enough that the last 2-3 reps feel hard.

The exercise selection matters. Compound movements (squat, deadlift, overhead press, row, pull-down) load multiple muscle groups simultaneously and produce more stimulus per minute than isolation exercises. The five fundamental movement patterns to cover across a training week are squat, hinge, push (vertical and horizontal), pull (vertical and horizontal), and carry or core. Most well-designed programmes for women over 40 cycle through these patterns across 2-3 weekly sessions.

The intensity matters for muscle building specifically. The 2017 Schoenfeld meta-analysis on low-load vs high-load training found that hypertrophy gains were similar across rep ranges as long as the sets were taken close to failure, but strength gains favoured heavier loads. For sarcopenia reversal, the practical implication is that loads producing genuine effort (RPE 7-8) in the 6-15 rep range are productive; very light weights for very high reps build endurance more than muscle.

The frequency matters. The 2016 Schoenfeld meta-analysis on training frequency found that training each muscle group twice a week produces marginally better hypertrophy than once a week, with smaller additional benefit from three times. For postmenopausal women, 2-3 full-body sessions per week or a 4-day upper/lower split hits the productive frequency range. More than four sessions a week often produces less benefit because recovery becomes the limiting factor.

The progression matters most of all. Without progressive overload (gradually increasing weight, reps or difficulty over weeks), training stops being effective within 6-8 weeks. The simplest progression model is “double progression”: pick a rep range (8-12), choose a weight you can lift for 8 reps with good form, add reps each session until you can do 12 reps for all sets with 1-2 reps in reserve, then add the smallest available weight increment and start back at 8 reps. This produces consistent week-to-week progression without complex planning.

Protein as the nutritional foundation

Adequate protein (1.4-1.6g per kg body weight per day, distributed across 3-4 meals) is required for resistance training to produce muscle gains in postmenopausal women. Phillips and colleagues’ 2016 review in Applied Physiology, Nutrition, and Metabolism identified this range as the requirement for older adults to maintain or build muscle, compared to the 0.8g/kg RDA originally calibrated for younger sedentary adults [4]. Most postmenopausal women in the UK and US eat 50-70g protein per day, well below the threshold.

The mechanism connects to anabolic resistance. Older muscle requires a larger protein dose to trigger maximal muscle protein synthesis than younger muscle. The leucine threshold (the amount of the essential amino acid leucine required to maximally stimulate muscle protein synthesis) appears to be roughly 2.5-3g per meal in older adults, which translates to roughly 25-35g of complete protein per meal. Below this threshold, the meal contributes less to muscle protein synthesis than its calorie content would suggest.

The distribution matters. Aragon and Schoenfeld’s work on protein timing has documented that meal-by-meal distribution affects muscle protein synthesis more than total daily intake alone [5]. Three or four meals each providing 25-35g of complete protein produces more cumulative muscle-building stimulus than one large protein dose plus several lower-protein meals. The practical translation: spread the protein across the day rather than concentrating it.

The sources matter less than the totals for most women. Animal proteins (eggs, fish, poultry, lean meat, dairy) tend to have complete amino acid profiles and high leucine content. Plant proteins typically need to be combined or consumed in larger quantities to match the same leucine dose. Whey protein supplements are practical for women who struggle to hit the daily target through whole foods alone; one scoop typically provides 25g of high-quality protein with 2.5-3g of leucine.

What 1.4-1.6g per kg actually looks like in food: for a 65kg woman, the daily target is 91-104g protein, distributed as roughly 25g per meal across four meals or 30g across three. Examples of 25g protein meals: 3-egg omelette with 30g cheese; tinned salmon (120g) with avocado on toast; 100g chicken breast with quinoa salad; Greek yogurt 200g with nuts and berries; cottage cheese 200g with fruit; salmon fillet 130g with vegetables; tofu and bean stir-fry (300g serving); chicken thighs 130g with sweet potato.

For deeper coverage of protein in this age range, see the dedicated protein for women over 50 guide.

Aerobic exercise: the complementary role

Aerobic exercise (walking, cycling, swimming) supports sarcopenia reversal through improved cardiovascular fitness, recovery support, mood and sleep effects, but does not build muscle on its own and cannot substitute for resistance training in this context. The case for aerobic exercise alongside strength training is strong but distinct from the case for it as a sarcopenia intervention.

The trial evidence is consistent. Cardio-only interventions in postmenopausal women produce cardiovascular benefits but minimal muscle preservation effects. Strength-only interventions produce muscle and bone benefits but smaller cardiovascular gains. The combination of strength plus aerobic produces broader health benefits than either alone, and the WHO and BMS physical activity guidelines reflect this by recommending both modalities.

For sarcopenia specifically, the aerobic component supports the strength component rather than replacing it. Walking improves recovery between strength sessions through gentle blood flow and reduced systemic inflammation. Zone 2 cardio improves mitochondrial function in muscle, which supports the metabolic capacity required for strength work. The aerobic component also addresses the cardiovascular and metabolic outcomes (insulin sensitivity, blood pressure, lipid profile) that affect overall health independently of muscle mass.

What works practically: 150 minutes of moderate aerobic activity per week, distributed across 3-5 sessions. Walking 30-45 minutes most days covers the dose. Swimming, cycling and gentle hiking work too. The intensity sits in Zone 2 (conversational pace) for most of this time, with optional 1-2 short HIIT sessions per week for additional cardiovascular stimulus.

What doesn’t work for sarcopenia reversal: replacing strength training with cardio in the hope that “exercise is exercise”. The mechanisms are different, and the muscle protein synthesis stimulus from cardio is much smaller than from progressive resistance training. Women who exercise extensively but only with cardio modalities continue losing muscle through perimenopause and postmenopause despite the time investment.

The dose that produces sarcopenia reversal

The dose that consistently produces sarcopenia reversal in the trial literature is 2-3 progressive resistance sessions per week plus 1.4-1.6g protein per kg body weight per day, sustained for at least 12-16 weeks for measurable muscle changes. This dose meets the WHO physical activity guidelines, the BMS recommendations for women in midlife, and the volumes used in most positive trials including Capel-Alcaraz 2022 and Liu and Latham 2009 [2][3].

The intensity matters specifically for muscle building. Loads challenging enough that the last 2-3 reps of each set feel hard (RPE 7-8) drive the muscle protein synthesis stimulus. Loads too light to require genuine effort don’t trigger the adaptation regardless of total volume. The 6-15 rep range is the productive zone for hypertrophy in this population, with 3-6 reps used for heavier compound lifts when bone density is also a goal.

The frequency matters. Two full-body sessions per week or a 4-day upper/lower split produces consistent muscle gains. Three full-body sessions hits the upper end of productive frequency for most postmenopausal women. Above four sessions, returns diminish sharply because recovery becomes the limiting factor.

The recovery infrastructure matters. Sleep (7-9 hours), protein intake throughout the day, and avoidance of severe caloric restriction all support the muscle-building response to training. The Trexler 2014 metabolic adaptation review documented how aggressive caloric restriction undermines muscle preservation; this is particularly relevant for women trying to lose weight while building muscle [8].

The timeline matters. Muscle changes are measurable on imaging at 8-16 weeks of consistent training; visible muscle definition typically appears at 6-12 weeks; functional strength gains start to register at 4-6 weeks. Trainees who stop at week 4 because they don’t see visible changes are cutting themselves off long before the largest muscle adaptations appear.

How long until you reverse sarcopenia

Expect functional strength gains within 4-6 weeks, visible muscle changes at 8-12 weeks, and meaningful body composition shifts at 12-26 weeks of consistent training plus adequate protein. This timeline matches the trial literature and applies to postmenopausal women starting from various baselines, with some individual variation based on starting muscle mass, training history and nutrition.

The progression is usually predictable. Weeks 1-2 are mostly nervous-system adaptation; the trainee gets more efficient at the movements without much actual muscle change, and weights can rise faster than the underlying muscle is growing. Weeks 3-6 bring early hypertrophy and noticeable strength gains. Weeks 6-12 are usually when visible muscle definition starts to appear, particularly in the shoulders and quadriceps where adaptation tends to show first. Weeks 12-26 bring meaningful body composition change and the “you can see I’ve been training” transition.

After the first year of consistent training, gains slow further. The “newbie gains” phase typically tapers around 6-12 months in. Year-two and beyond progression looks like adding 2.5kg every 4-6 weeks rather than every week, and that’s normal and healthy. Sustained training across years continues to maintain or build muscle even at the slower year-two pace.

Reasonable benchmarks to track over 12 weeks:

• Strength on key lifts: squat, deadlift, overhead press, row. Track every fortnight. Should rise consistently.
• Functional measures: chair stand reps in 30 seconds, single-leg stand time, stair-climbing capacity. Should improve.
• Visible muscle changes: shoulders and quadriceps tend to show changes first.
• Body composition (DEXA scan if available): baseline plus 6-month repeat shows lean mass changes precisely.
• Daily protein intake: track for 2 weeks to confirm you’re hitting 1.4-1.6g per kg.

Don’t rely on scale weight as the primary metric. Muscle gain combined with fat loss often produces stable or slightly decreasing scale weight while body composition improves substantially. The scale undersells the change; the strength and functional measures are more reliable indicators.

When exercise isn’t enough: clinical sarcopenia and severe cases

Exercise alone may not be enough when sarcopenia is severe and accompanied by underlying chronic illness, when nutritional status is significantly impaired, or when functional decline has reached the level of frailty. The EWGSOP2 diagnostic framework distinguishes between confirmed sarcopenia (low muscle strength plus low muscle quantity or quality) and severe sarcopenia (low strength, low quantity, plus low physical performance). The latter often warrants multidisciplinary management including physiotherapy, nutritionist input, and assessment for underlying medical contributors [6].

Red flags worth raising with a GP rather than trying to self-direct exercise:

• Significant unintentional weight loss (over 5% of body weight in 6 months without trying).
• Severe functional decline (difficulty rising from a chair, inability to climb stairs, frequent falls).
• Symptoms of underlying chronic disease (chronic fatigue, persistent infections, breathlessness on minimal exertion).
• Diagnosed conditions associated with secondary sarcopenia (chronic kidney disease, heart failure, COPD, cancer, autoimmune disease).
• Sustained low protein intake from poor appetite, dental issues, or restricted eating patterns.
• Unable to start or sustain a training programme due to pain, instability, or rapid fatigue.

HRT is relevant to the sarcopenia picture for women in early postmenopause. The Maltais 2009 review and subsequent literature suggest HRT may enhance the muscle-building response to resistance training, particularly when started in early postmenopause [1]. HRT is not a treatment for sarcopenia per se but the metabolic and hormonal effects appear to support muscle maintenance. The decision is between you and a menopause-trained GP based on the full symptom and risk profile.

For women with established frailty or severe sarcopenia, the intervention typically requires supervised physiotherapy or geriatric rehabilitation rather than self-directed home programmes. The principles are the same (progressive resistance training plus adequate protein) but the supervision and adaptation matter for safety and adherence. NHS provision varies by region; private rehabilitation specialists are available where NHS access is limited.

A sample week for sarcopenia reversal

Here’s a 7-day template combining the strongest evidence-backed interventions for sarcopenia reversal: 3 strength sessions, daily walking, 1 yoga or recovery session, 2 genuine rest days, with protein hit at 25-35g per meal across the day. Adjust to your fitness baseline. If you’ve never trained, start with 2 strength sessions and add the third in week 4.

Day	Main session	Protein target
Monday	Strength A: full-body, 40 min. Squat, hinge, push, pull, carry. RPE 7-8.	91-104g across 4 meals
Tuesday	Brisk walk 30-45 min	Same
Wednesday	Strength B: full-body or upper/lower, 40 min. Different exercises than Monday.	Same
Thursday	Walk or gentle yoga, 30-45 min	Same
Friday	Strength C: full-body, 40 min. Compound focus.	Same
Saturday	Long walk or hike, 60-90 min	Same
Sunday	Rest or restorative practice	Same

Why this structure? Three strength sessions hit the dose Capel-Alcaraz 2022 supports for muscle preservation and gain in postmenopausal women [2]. The walking provides the cardiovascular and recovery support. The protein target throughout meets the Phillips 2016 threshold for muscle preservation in older adults [4]. Two rest days protect against the over-training pattern that often derails progress.

Self-tests and diagnostic markers for sarcopenia

Several practical tests identify whether sarcopenia is becoming a clinical concern. The EWGSOP2 framework uses three components for clinical diagnosis: low muscle strength, low muscle quantity, and low physical performance. Some of these can be assessed at home; others require clinical input.

Grip strength is the strongest single predictor of clinical sarcopenia and overall function. Hand-held dynamometers (the Jamar dynamometer is the clinical standard) measure grip strength precisely. The EWGSOP2 cutoff for low grip strength in women is under 16kg. At-home assessment is harder without the device, but consistent difficulty opening jars, carrying shopping, or holding heavy items suggests grip strength worth checking.

30-second sit-to-stand test assesses lower body strength and function. Sit in a standard chair without arms, arms folded across chest. Stand up and sit down as many times as you can in 30 seconds without using your hands. Functional benchmark: under 12 reps in 60s women aged 60-69 is below average; under 10 is concerning; under 8 in any age over 60 indicates significant functional limitation. The test is validated as predicting falls and disability risk.

Gait speed measures usual walking pace over 4-6 metres. Walk at your normal pace and time the duration; speed below 0.8 metres per second is below average and below 0.6 m/s indicates clinical concern. Most adults walk at 1.0-1.4 m/s; declining gait speed often precedes other signs of functional decline.

Calf circumference is a rough proxy for lower body muscle mass. Measure the largest part of the calf with a tape measure. Calf circumference under 31cm in women has been associated with low muscle mass in clinical studies. The measure is crude but easy and tracks changes over time.

DEXA scan with body composition provides precise lean mass measurement and is the clinical gold standard. The lean mass at the appendicular sites (arms and legs) is the relevant measurement; below the EWGSOP2 cutoff (under 15.0 kg total for women, depending on the specific protocol) indicates low muscle mass.

For most women without overt symptoms, the home-based tests (sit-to-stand, gait speed, grip strength approximation) provide useful tracking over years. Concerning results warrant GP review and possible referral for formal sarcopenia assessment. Early identification allows the exercise and protein interventions to start before functional decline becomes substantial.

HRT and sarcopenia: what the evidence shows

HRT may modestly enhance the muscle-building response to resistance training in early postmenopausal women through restored oestrogen signalling in muscle, but exercise produces meaningful muscle preservation effects regardless of HRT status. The decision about HRT depends on individual symptom profile and risk factors rather than on muscle outcomes alone; the muscle benefit is a secondary consideration.

The biology supports a role for oestrogen in muscle. Oestrogen receptors in muscle tissue support protein synthesis and satellite cell activation. Premenopausal women have stronger muscle-building responses to a given training stimulus than postmenopausal women, partly because of the oestrogen contribution. HRT replacing some of the oestrogen that’s been lost may modestly restore the response.

The evidence base is reasonable but not extensive. Small trials have suggested that HRT-using postmenopausal women preserve more muscle and gain more strength from resistance training than non-users at matched training volumes. Pöllänen and colleagues’ work in Finland has documented some of these effects. The clinical position from the British Menopause Society and The Menopause Society is that HRT is appropriate for women with menopausal symptoms warranting medical management; the muscle benefit is a secondary consideration.

For women on HRT who are training, the practical implication is that the standard sarcopenia interventions (resistance training plus adequate protein) work at least as well, and possibly slightly better. For women without HRT, the same interventions still work substantially well; the absolute muscle gains may be modestly lower but the dose-response relationship remains intact.

The decision about HRT shouldn’t be made on muscle outcomes alone. Symptoms (vasomotor, mood, vaginal, sleep), risk factors, family history, and personal preference all matter. The dedicated exercise after menopause guide covers the broader HRT considerations.

Programmes that fit sarcopenia prevention and treatment

The programmes that work best for sarcopenia reversal share three features: progressive resistance training as the foundation, structured progressions that allow consistent overload, and reasonable session lengths that fit alongside the rest of life. Below are the platforms reviewed at herdailyfit.com/programs that fit this brief.

Caroline Girvan CGX (7.8 overall, 7.5 for Women Over 40, 10 for Muscle Potential). Heavy compound strength, four sessions a week. Strongest fit for women who want maximal muscle results from home dumbbell training. Full review at the CGX programme page.

EvolveYou (6.0 overall, 8 for Muscle Potential). Multiple hypertrophy-focused tracks with detailed exercise libraries. Better fit for intermediate lifters with established training base. Full review at the EvolveYou programme page.

Burn360 (8.3 overall). Compound dumbbell strength in 20-25 minute sessions with linear progression. Best fit for women with limited training time who want strength and muscle results without 50-minute sessions. Full review at the Burn360 programme page.

Evlo ([?] overall). DPT-designed strength training with explicit attention to joint-friendly loading. Best for women whose previous training has aggravated joints. Full review at the Evlo programme page.

What I’d avoid for sarcopenia reversal specifically: programmes prescribing exclusively bodyweight training (load doesn’t progress enough), Pilates-only routines (load is too low), yoga-only routines (load is too low), and dance cardio routines (load is too low for muscle building even when calorie burn is high).

Common mistakes that compromise sarcopenia reversal

Five common mistakes compromise sarcopenia reversal: under-eating protein, sticking with light weights indefinitely, prioritising cardio over strength, abandoning programmes before muscle adaptations occur, and assuming “any exercise” prevents muscle loss. Each one is fixable.

Under-eating protein is the most common error. Most postmenopausal women in the UK and US eat 50-70g protein per day, well below the 91-104g target for a 65kg woman. Without adequate protein, training produces strength gains but minimal muscle gain because the building blocks aren’t available. Track intake for two weeks to see where you actually sit, then build up.

Sticking with light weights indefinitely keeps the training stimulus below the muscle-building threshold. Progressive overload requires the weights to increase over weeks. The fix is double progression: when you can do the top of the rep range with reps in reserve, add the smallest available increment.

Prioritising cardio over strength is the configuration that has been failing women in midlife for decades. Cardio is supportive; strength is the primary intervention for sarcopenia. The fix is reversing the priority: strength training as the foundation, cardio as the complement.

Abandoning at week 4 because no visible change has occurred cuts trainees off before the largest muscle adaptations appear. Twelve weeks is the minimum useful test for muscle outcomes; six months is when meaningful body composition change becomes obvious. Sustained training over 1-2 years is when the trajectory really shifts.

Assuming “any exercise” prevents muscle loss is the most prevalent piece of misinformation in this space. Walking is good for many things; it doesn’t build or even fully maintain muscle. Yoga is good for many things; it doesn’t build muscle. Pilates is good for many things; it doesn’t build muscle to the same degree as progressive resistance training. Sarcopenia reversal requires loading that drives muscle protein synthesis, which requires resistance training with progressive overload.

Creatine and other supplements: what helps and what doesn’t

Creatine monohydrate has the strongest evidence among supplements for muscle preservation and gain in older women, with multiple trials documenting benefit when combined with resistance training. Other supplements (HMB, vitamin D, omega-3) have smaller and less consistent effects. None substitute for adequate protein and resistance training; they’re optional adjuncts to address marginal additional gains.

Creatine is the most-evidenced supplement for sarcopenia in older adults. Multiple trials have documented that creatine monohydrate (typically 3-5g daily) combined with resistance training produces larger gains in muscle mass and strength than training alone in postmenopausal women. The Candow 2019 review in Nutrients covered the evidence for creatine in older adults and concluded it’s safe, well-tolerated and consistently beneficial when paired with training. The cost is low (creatine monohydrate is one of the cheapest supplements per gram), the evidence base is strong, and the side effect profile is benign in healthy women without kidney disease.

HMB (beta-hydroxy beta-methylbutyrate) has more variable evidence. Some trials in frail older adults show benefit; trials in healthier postmenopausal women are more mixed. The cost is higher than creatine and the evidence weaker; for most women creatine is the better starting point if a single supplement is being considered.

Vitamin D supports muscle function alongside its bone density role; women with low vitamin D status often see modest improvements in muscle strength when status is corrected. The relevant target is keeping serum 25(OH)D above 50 nmol/L, which most women in northern latitudes need supplementation to achieve in winter months. Omega-3 fatty acids (EPA/DHA from fish or algae sources) have some evidence for supporting muscle protein synthesis in older adults at higher doses (2-4g per day), though the effect size is small.

The honest framing: protein adequacy plus resistance training plus sleep delivers the bulk of available benefit. Creatine adds a meaningful but modest increment. Vitamin D status correction is worth doing if deficient. The rest is largely optional.

Where the evidence is still evolving

Three areas of the menopause-sarcopenia literature are still genuinely under-studied: the optimal protein intake for postmenopausal women specifically (as distinct from older adults broadly), the interaction between HRT and resistance training on muscle outcomes, and whether higher-intensity strength training (LIFTMOR-style heavy loading) produces additional muscle benefits beyond moderate-load training.

The protein question is the biggest gap. The Phillips 2016 recommendation of 1.4-2.0g per kg per day is well-evidenced for older adults broadly. Whether postmenopausal women specifically benefit from intakes at the higher end of this range (1.6-2.0g/kg) given the hormonally-driven anabolic resistance is suggested by some emerging work but not yet definitively established [4].

The HRT-strength interaction is interesting. HRT may enhance muscle protein synthesis response in early postmenopausal women, and resistance training improves muscle in postmenopausal women. Whether their effects are additive, redundant, or synergistic in head-to-head trials has not been studied extensively. The current evidence supports both interventions as appropriate for symptomatic women in early postmenopause.

The intensity question is partially addressed by the LIFTMOR trial and related heavy-loading research, which demonstrated that postmenopausal women can safely train at 80-85% of one-rep maximum with bone density gains. Whether this heavy loading produces meaningfully more muscle gain than moderate loading (60-75% 1RM) is plausible but not definitively established.

Glossary

Anabolic resistance: the reduced ability of older muscle to respond to dietary protein and training stimulus. Partially reversible through resistance training.

EWGSOP2: European Working Group on Sarcopenia in Older People, second consensus. Provides current diagnostic criteria for sarcopenia.

Hypertrophy: muscle growth. The increase in muscle cross-sectional area produced by appropriate training stimulus.

IGF-1: insulin-like growth factor 1. Anabolic hormone that supports muscle protein synthesis. Rises acutely with resistance training.

Lean mass: body weight minus fat mass. Includes muscle, bone, organs, water. The clinically relevant component for sarcopenia is appendicular lean mass (arms and legs).

Leucine threshold: the amount of leucine required to maximally stimulate muscle protein synthesis. Roughly 2.5-3g per meal in older adults, equivalent to 25-35g of complete protein.

mTOR: mammalian target of rapamycin. Central molecular switch for muscle protein synthesis. Activated by leucine and resistance training.

Muscle protein synthesis (MPS): the cellular process by which new muscle tissue is built. Stimulated by protein intake and resistance training.

Sarcopenia: age-related loss of muscle mass, strength and function. Accelerates after menopause; largely reversible through training and protein.

Satellite cells: muscle stem cells that contribute to muscle growth and repair. Activated by training and modulated by oestrogen.

References

1. Maltais ML, Desroches J, Dionne IJ. Changes in muscle mass and strength after menopause. J Musculoskelet Neuronal Interact. 2009;9(4):186-197. PubMed: 19949277
2. Capel-Alcaraz AM, García-López H, et al. Effects of resistance training on body composition and physical function in postmenopausal women: a systematic review and meta-analysis. 2022. PubMed: 35055015
3. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;(3):CD002759. PubMed: 19588334
4. Phillips SM, Chevalier S, Leidy HJ. Protein “requirements” beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab. 2016;41(5):565-572. PubMed: 26960445
5. Aragon AA, Schoenfeld BJ. Nutrient timing revisited: is there a post-exercise anabolic window? J Int Soc Sports Nutr. 2013;10(1):5. PubMed: 23360586
6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16-31. PubMed: 30312372
7. Westcott WL. Resistance training is medicine: effects of strength training on health. Curr Sports Med Rep. 2012;11(4):209-216. PubMed: 22777332
8. Trexler ET, Smith-Ryan AE, Norton LE. Metabolic adaptation to weight loss: implications for the athlete. J Int Soc Sports Nutr. 2014;11:7. PubMed: 24571926
9. Schoenfeld BJ, Grgic J, Ogborn D, Krieger JW. Strength and hypertrophy adaptations between low- vs. high-load resistance training: a systematic review and meta-analysis. J Strength Cond Res. 2017;31(12):3508-3523. PubMed: 28834797
10. Schoenfeld BJ, Ogborn D, Krieger JW. Effects of resistance training frequency on measures of muscle hypertrophy: a systematic review and meta-analysis. Sports Med. 2016;46(11):1689-1697. PubMed: 27102172
11. Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res. 2018;33(2):211-220. PubMed: 28975661
12. Helms ER, Zinn C, Rowlands DS, Brown SR. A systematic review of dietary protein during caloric restriction in resistance trained lean athletes. Int J Sport Nutr Exerc Metab. 2014;24(2):127-138. PubMed: 24092765
13. British Menopause Society. Tools for clinicians: muscle and bone in the menopause. Available at: thebms.org.uk
14. NHS. Physical activity guidelines for adults aged 19 to 64. Available at: nhs.uk
15. The Menopause Society. Body composition and the menopause. Available at: menopause.org
16. World Health Organization. WHO guidelines on physical activity and sedentary behaviour, 2020. Available at: who.int

Frequently Asked Questions